Why the CEO of Sean Parker’s cancer institute left to help the ‘cellular police’ arrest diseases like diabetes
Cell therapy pioneer Jeff Bluestone is launching a new biotech company with $40 million in venture funding, aiming to corral the power of a special type of cell that could shut down inflammatory autoimmune diseases.
The 12-employee South San Francisco company, called Sonoma Biotherapeutics Inc., includes superstar founders, staff, board and investors, starting with Bluestone, who spent the past four-plus years as president and CEO of billionaire Sean Parker’s San Francisco-based cancer immunotherapy institute….